A5014103994- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Protein Degradation and Inhibitors
- Prostate Cancer Treatment and Research
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
- Radiopharmaceutical Chemistry and Applications
- Schizophrenia research and treatment
- Diabetes Treatment and Management
- Lung Cancer Treatments and Mutations
- Chronic Myeloid Leukemia Treatments
- Statistical Methods in Clinical Trials
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Treatment and Pharmacology
- Hepatitis C virus research
- Gastrointestinal Tumor Research and Treatment
- Psoriasis: Treatment and Pathogenesis
- Cancer, Lipids, and Metabolism
- Pharmaceutical studies and practices
- Immunodeficiency and Autoimmune Disorders
- Bipolar Disorder and Treatment
- Diabetes Management and Research
- Pharmaceutical Economics and Policy
- Monoclonal and Polyclonal Antibodies Research
Janssen (Belgium)
2015-2024
National University of Singapore
2023
Janssen (United States)
2014-2022
The electronic Schizophrenia Treatment Adherence Registry (e-STAR) is a prospective, observational study of patients with schizophrenia designed to evaluate long-term treatment outcomes in routine clinical practice.Parameters were assessed at baseline and 3 month intervals for 2 years initiated on risperidone long-acting injection (RLAI) (n=1345) or new oral antipsychotic (AP) (n=277; 35.7% 36.5% olanzapine, respectively) Spain. Hospitalization prior therapy was by retrospective chart...
Background:Inpatient care to manage relapse of patients with schizophrenia contributes greatly the overall financial burden treatment. The present study explores what extent this is influenced by duration illness.Methods:Medical and pharmaceutical claims data for diagnosed (ICD-9 295.xx) were obtained from PharMetrics Integrated Database, a large, regionally representative US insurance database, period 1998–2007. Recently (n = 970) chronic 2996) distinguished based on ICD-9 295.xx...
Patients with triple-class-exposed relapsed/refractory multiple myeloma (TCE-RRMM) have a poor prognosis and limited treatment options. Teclistamab, B-cell maturation antigen × CD3 bispecific antibody, was studied in patients TCE-RRMM the single-arm MajesTEC-1 study. To assess relative effectiveness of teclistamab versus real-world physician's choice therapy (RWPC), adjusted comparisons were performed using individual patient data from LocoMMotion, prospective study TCE-RRMM. An external...
Talquetamab, a bispecific antibody targeting GPRC5D × CD3, is approved for the treatment of patients with triple-class -exposed (TCE) relapsed/refractory multiple myeloma (RRMM) on basis results from phase I/II MonumenTAL-1 trial. The relative effectiveness talquetamab vs. real-world physician's choice therapy (RWPC) was assessed using adjusted comparisons. An external control arm (subcutaneously administered 0.4 mg/kg weekly [QW] and 0.8 every other week [Q2W]) created two observational...
This study estimated the comparative efficacy of ciltacabtagene autoleucel (cilta-cel) versus approved idecabtagene vicleucel (ide-cel) dose range 300-460 × 106 CAR-positive T-cells for treatment patients with relapsed or refractory multiple myeloma (RRMM) who were previously treated a proteasome inhibitor, an immunomodulatory drug, and anti-CD38 monoclonal antibody (i.e. triple-class exposed) using matching-adjusted indirect comparisons (MAICs).MAICs performed individual patient data...
Abstract Background Respiratory syncytial virus (RSV) is a leading cause of hospitalizations in children (≤5 years age); limited data compare burden by age. Methods This single-center retrospective study included age) hospitalized for >24 hours with reverse-transcription polymerase chain reaction (RT-PCR)–confirmed RSV infection (2015–2018). Hospital length stay (LOS), intensive care unit (ICU) admissions, ICU LOS, supplemental oxygen, and medication use were assessed. Multivariate...
This retrospective cohort study investigated the relation between different measures of glycemic exposure and micro- macrovascular complications among patients with type 2 diabetes.The analysis included receiving oral antihyperglycemic agents 1 January 2006 31 December 2014 from General Practitioner Database PHARMO Network. All recorded HbA1c levels during follow-up were used to express in four ways: index HbA1c, time-dependent exponential moving average (EMA) burden. Association...
Patients with advanced, epidermal growth factor receptor (EGFR)-mutated, non-small cell lung cancer (NSCLC) Exon 20 insertion mutations (Exon20ins) have poor prognoses, exacerbated by a previous lack of specific treatment guidelines and unmet need for targeted therapies. Amivantamab, an EGFR MET bispecific antibody, demonstrated efficacy tolerability in patients advanced EGFR-mutated NSCLC Exon20ins following platinum-based therapy CHRYSALIS (NCT02609776; Cohort D+). Since was single-arm,...
Gastrointestinal (GI) adverse effects are common with oral opioid treatment.To estimate the costs associated GI events after short-acting treatment, from payer perspective.Medical and pharmacy claims PharMetrics' Patient-Centric Database were used to identify opioid-naïve patients who received a new prescription for oxycodone- or hydrocodone-containing immediate-release products between 2002 2006. Health-care resource use determined ICD-9 CM (International Classification of Diseases-9th...
Ciltacabtagene autoleucel (cilta-cel) is a chimeric antigen receptor T-cell therapy studied in patients with multiple myeloma exposed to three classes of treatment the single-arm CARTITUDE-1 study. To assess effectiveness cilta-cel compared real-world clinical practice (RWCP), we performed adjusted comparisons using individual patients’ data from and LocoMMotion, prospective, multinational study triple-class treatment. Comparisons were inverse probability weighting. In CARTITUDE-1, 113...
Summary Chronic hepatitis C virus ( HCV ) infection places a considerable economic burden on health services. Cost‐effectiveness analyses of antiviral treatment for patients with chronic are dependent assumptions about cost reductions following sustained virological response SVR to therapy. This study quantified the medium‐term difference in resource usage and costs depending outcome. Retrospective chart review genotype 1 who had received at least 2 months pegylated interferon ribavirin...
Daratumumab is a human CD38‐directed monoclonal antibody approved in the United States as monotherapy for patients with multiple myeloma (MM) who have received ≥3 prior lines of therapy (LOTs), including proteasome inhibitor (PI) and an immunomodulatory agent (IMiD) or are double refractory to PI IMiD, combination lenalidomide/dexamethasone bortezomib/dexamethasone MM ≥1 LOT. This study compared efficacy daratumumab versus historical controls through adjusted treatment comparison....
Abstract Introduction Ciltacabtagene autoleucel (cilta‐cel) is a novel chimeric antigen receptor T‐cell therapy that being evaluated in the CARTITUDE‐1 trial (NCT03548207) patients with relapsed or refractory multiple myeloma (RRMM) who received as part of their previous an immunomodulatory drug, proteasome inhibitor, and anti‐CD38 monoclonal antibody (i.e., triple‐class exposed). Given absence control arm CARTITUDE‐1, this study assessed comparative effectiveness cilta‐cel physician's...
This study used the latest available data cuts from CARTITUDE-1 and KarMMa clinical trials to update previously published matching-adjusted indirect treatment comparisons (MAICs) assessing comparative efficacy of ciltacabtagene autoleucel (cilta-cel) versus FDA-approved idecabtagene vicleucel (ide-cel) dose range 300 450 × 106 CAR-positive T-cells in patients with relapsed or refractory multiple myeloma (RRMM) who were treated a proteasome inhibitor, an immunomodulatory drug, anti-CD38...
Head-to-head comparisons through randomized controlled trials (RCTs) provide high-quality evidence to inform healthcare decisions. In their absence, indirect are often performed; however, is limited on how valid matching-adjusted comparison (MAIC)-based comparative efficacy estimates vs. RCT-based estimates.Compare MAIC and RCT results of guselkumab secukinumab ixekizumab insight into the validity generated using methods.Previously reported from MAICs were compared with ECLIPSE IXORA-R RCTs...
To construct a model to predict preference-adjusted EuroQol 5D (EQ-5D) health utilities for patients with metastatic castrate-resistant prostate cancer (mCRPC) using the disease-specific health-related quality of life (HRQoL) measure, functional assessment therapy-prostate (FACT-P).HRQoL data were collected from mCRPC who enrolled in an observational study conducted 47 centers across six European Union countries. Utility values generated UK-specific EQ-5D value set. The predictive validity...
Abstract Aims Studies have shown that bortezomib retreatment is effective in relapsed/refractory multiple myeloma (MM). The observational, prospective electronic VELCADE ® OBservational Study (eVOBS) study assessed bortezomib‐based therapies for patients with MM everyday practice. Here, we report on those receiving bortezomib. Methods Consenting adults scheduled to receive were enrolled at 162 sites across Europe, Canada, Brazil, Russia, and Turkey between 2006 2010. Retrospective data prior...
To evaluate the overall survival (OS) of patients with chronic lymphocytic leukemia (CLL) receiving either ibrutinib monotherapy as a first-line (1L) treatment or chemotherapy/chemoimmunotherapy-based (CT/CIT) regimens in 1L followed by second line (1L CT/CIT-2L ibrutinib) after disease progression emulating randomized trial comparing both sequences.
To estimate the comparative efficacy of ciltacabtagene autoleucel (cilta-cel) versus idecabtagene vicleucel (ide-cel) in patients with relapsed/refractory multiple myeloma (RRMM) treated 2-4 prior lines therapy.